



BIOMAN<sup>4R2</sup>



# Success Story

## FINANCIAL SUPPORT PROGRAM



*"Gate2Brain platform technology will bring therapies closer to patients and clinical practice, going beyond societal and economic barriers to provide medicines for everyone, everywhere. Thus, Gate2Brain needed to analyze and understand the specific requirements for applying to EAP in the EU, in order to translate the clinical results obtained during the clinical trial to the clinical practice in the shortest period of time. The financial support received by BioMan4R2 had a great impact on the Market Access strategy of Gate2Brain."*



Co-funded by  
the European Union



## RESILIENCE FOR REGIONAL BIOMANUFACTURING AND MEDICAL TECHNOLOGY ECOSYSTEM

*“Gate2Brain team position itself as a mission-driven company with the goal to implement the pillars of the Recovery and Resilience Facility. Gate2Brain contributes by **1) Improving the treatment** of brain diseases with the development of a peptide-based technology that helps drugs to reach the brain; **2) Boosting innovation in the field of brain drug delivery industry** creating economic opportunities for EU companies developing brain treatments; and **3) Enhancing the resilience of the healthcare system** offering a more effective and accessible treatment opportunities that will reduce economic and social burdens derived from brain diseases.”*

## IMPACT

*“Studying **EAPs programs and Market Access** of G2B-002, which has been validated in a preclinical setting, will have a huge impact after clinical validation. This approach, considering investor’s opinion, may lead to an early investment for G2B-002 development. The inclusion of G2B-002 in an EAPs will have a huge financial benefit. EAPs can earn early revenues in the countries where early access through named patient programs can be charged by the countries. EAPs can be immensely useful in early market penetration leading to increased acceptance and uptake by physicians and patients after the commercial launch of the product.”*



Co-funded by  
the European Union